Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Semaglutide UK status: what changed

Semaglutide remains prescription-only in the UK, with 2026 changes to Wegovy doses, tablets, liver-disease use and product safety information.

Why we wrote this. The 2026 UK record includes several product-specific semaglutide changes that should not be collapsed into molecule-wide approval claims.

In this article (8 sections)
  1. The current product map
  2. What prescription-only status means
  3. January 2026: a higher Wegovy dose
  4. February 2026: the NAION safety update
  5. June and July 2026: new authorised uses
  6. The Rybelsus formulation transition
  7. What did not change
  8. Who to talk to

Semaglutide is authorised in the UK as a prescription-only medicine in several defined products and indications. The product name matters. Wegovy, Ozempic and Rybelsus are not interchangeable labels for any item that claims to contain semaglutide. Each authorisation covers a specific formulation, presentation and use. A seller vial is not an authorised product simply because the label names the same active ingredient.

The UK position changed materially during the past twelve months. The MHRA approved a higher Wegovy dose for adults with obesity in January 2026, added a rare eye-risk warning across Wegovy, Ozempic and Rybelsus in February, approved the first semaglutide tablet for weight management in June, and granted Wegovy a conditional authorisation for a form of liver disease in July[1][2][3][4]. These are product-specific changes, not permission for unlicensed semaglutide sales.

The current product map

Wegovy is an authorised semaglutide product associated with weight management and other approved uses. Ozempic is an injectable semaglutide product for type 2 diabetes. Rybelsus is an oral semaglutide product for type 2 diabetes. In February 2026 the MHRA's safety update named all three products when it added information about non-arteritic anterior ischaemic optic neuropathy, or NAION, a very rare eye condition[2].

In June 2026, the MHRA approved a Wegovy tablet for weight loss and weight management. It described this as the UK's first GLP-1 receptor agonist tablet for that purpose and confirmed that it remained prescription-only. The agency also said it was not then available through the NHS, pending the separate health-service access process[3].

These distinctions are why our semaglutide overview treats the molecule and finished products separately. The UK regulation hub covers the national framework. Neither page treats a research vial as Wegovy, Ozempic or Rybelsus.

What prescription-only status means

The MHRA says the authorised GLP-1 medicines used for weight management should be taken as prescribed by a healthcare professional. It advises the public to avoid unregulated websites and social-media sellers and to check that an online pharmacy is registered with the General Pharmaceutical Council[5]. This is the practical dividing line between authorised prescribing and the grey market.

Regulation 46 of the Human Medicines Regulations 2012 prohibits selling or supplying, or offering to sell or supply, an unauthorised medicinal product unless an exception applies[6]. An authorised semaglutide brand therefore does not legalise every formulation sold under the molecule name. A copied pen, altered concentration or seller vial remains a different product.

Private prescribing does not remove these controls. A legitimate private route still requires a prescriber and regulated pharmacy supply. A website offering semaglutide without a prescription is not providing an easier version of the same authorised route.

January 2026: a higher Wegovy dose

The MHRA announced that it had approved a maximum Wegovy dose of up to 7.2 mg per week on 6 January 2026 for adult patients with obesity. The agency limited that change to adults with a BMI of 30 kg/m² or higher using Wegovy for weight management. It said the change did not apply to overweight patients below that BMI threshold or to people using Wegovy for cardiovascular-risk reduction[1].

This was an extension to a defined authorised product and population. It did not create a general high-strength semaglutide category. A seller cannot cite the decision as authority for a vial, copied pen or self-directed protocol. Treatment strength remains a prescribing decision under the approved product information.

February 2026: the NAION safety update

On 5 February 2026, the MHRA advised that semaglutide treatment may be very rarely associated with NAION, which can cause sudden, painless loss or deterioration of vision, typically in one eye. The update covered Wegovy, Ozempic and Rybelsus and required product information to reflect the risk[2].

The regulator advised urgent ophthalmological assessment for sudden partial or complete vision loss and asked healthcare professionals and patients to report suspected reactions through Yellow Card[2]. This was a safety-information change, not a withdrawal of semaglutide authorisations.

June and July 2026: new authorised uses

The June approval added a daily Wegovy tablet for adults meeting the authorised weight-management criteria. The MHRA separated approval from NHS availability, stating that the tablet was approved in the UK but was not currently available through the NHS[3]. This is a useful reminder that marketing authorisation and publicly funded access are different decisions.

On 3 July 2026, the MHRA conditionally authorised Wegovy injection to treat metabolic-associated steatohepatitis, or MASH, in adults with moderate-to-advanced liver fibrosis. The agency said further results from an ongoing study must be submitted and that it would review new information at least annually[4]. It also said NHS access for that indication depended on a NICE appraisal.

Conditional authorisation is still an authorisation for the stated product and indication, subject to further evidence obligations. It is not evidence that all semaglutide products are conditionally approved for liver disease. Ozempic, Rybelsus and a seller vial do not inherit Wegovy's MASH indication.

The Rybelsus formulation transition

A separate change began in December 2025. The MHRA warned about a transition between original and new Rybelsus tablet formulations. The new formulation has greater bioavailability, so lower stated strengths are bioequivalent to the older tablets. The regulator warned that trying to match the old milligram numbers by using multiple new tablets could cause overdose and medication error[7].

This is another product-identity issue. The change applied to Rybelsus tablets and their authorised transition. It did not change Wegovy injection or create equivalence with a compounded or seller-supplied oral semaglutide product.

What did not change

Semaglutide remained prescription-only. The MHRA's July 2026 public advice named Wegovy among authorised prescription weight-loss medicines and warned against unregulated sellers[5]. Authorised products continued to require clinical prescribing, regulated manufacture and pharmacy supply.

The changes also did not authorise retatrutide. The MHRA explicitly contrasted authorised medicines with retatrutide, which remained unauthorised[5]. See the retatrutide UK status article for that separate record. Tirzepatide is another distinct active ingredient and product family.

Nor did these authorisations create one broad semaglutide indication. Weight management, cardiovascular-risk reduction, type 2 diabetes and MASH have different product information, populations and access decisions. The Wegovy tablet approval did not rewrite the authorised uses of Ozempic or Rybelsus. The conditional MASH decision did not make every semaglutide presentation a liver-disease medicine. Readers should check the product name and indication together rather than treating the active ingredient as the whole regulatory record.

Who to talk to

Questions about whether an authorised semaglutide product is suitable belong with a qualified prescriber who knows your medical history. Questions about a dispensed pack can be taken to the pharmacist. Suspected side effects or quality problems can be reported through the MHRA Yellow Card scheme.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Regulatory disclaimer: This page reflects our understanding of the UK regulatory status as of 8 November 2026. Regulations and product information change. Verify with the MHRA before making any decision. PeptideMethods.com is not a law firm and does not provide legal advice.

Frequently asked

Is semaglutide authorised in the UK?

Yes, in defined prescription-only products including Wegovy, Ozempic and Rybelsus. Their formulations and authorised uses differ. A vial sold only under the molecule name does not inherit those authorisations.

What changed for Wegovy in the UK in 2026?

The MHRA approved a higher dose for certain adults with obesity in January, a tablet for weight management in June, and a conditional MASH indication for Wegovy injection in July.

What was the 2026 semaglutide eye warning?

The MHRA added information about a very rare association with NAION, which can cause sudden vision loss. The update covered Wegovy, Ozempic and Rybelsus and advised urgent specialist assessment for sudden vision loss.

Does UK approval mean semaglutide is available on the NHS?

Not automatically. Marketing authorisation and NHS funding are separate. The MHRA said the newly approved Wegovy weight-management tablet was not then available through the NHS, and MASH access depended on NICE appraisal.

Can semaglutide be bought in the UK without a prescription?

Authorised semaglutide medicines are prescription-only. The MHRA advises avoiding sellers that offer prescription GLP-1 medicines without a prescription and checking that online pharmacies are registered.

Sources

  1. [1]MHRA: up to 7.2 mg Wegovy dose approved for certain adults with obesityTier 1 · primary↩
  2. [2]MHRA: semaglutide products and the very rare risk of NAIONTier 1 · primary↩
  3. [3]MHRA: first GLP-1 tablet for weight loss approved in the UKTier 1 · primary↩
  4. [4]MHRA: Wegovy conditionally approved to treat MASHTier 1 · primary↩
  5. [5]MHRA: No summer shortcut for safe weight lossTier 1 · primary↩
  6. [6]Human Medicines Regulations 2012, regulation 46Tier 1 · primary↩
  7. [7]MHRA: Rybelsus transition to a new formulation and medication-error riskTier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars